Nishikawa Hiroyoshi, Qian Feng, Tsuji Takemasa, Ritter Gerd, Old Lloyd J, Gnjatic Sacha, Odunsi Kunle
Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
J Immunol. 2006 May 15;176(10):6340-6. doi: 10.4049/jimmunol.176.10.6340.
We have recently reported that NY-ESO-1-specific naive CD4+ T cell precursors exist in most individuals but are suppressed by CD4+CD25+ regulatory T cells (Tregs), while memory CD4+ T cell effectors against NY-ESO-1 are found only in cancer patients with spontaneous Ab responses to NY-ESO-1. In this study, we have analyzed mechanisms of CD4+ T cell induction following peptide vaccination in relation to susceptibility to Tregs. Specific HLA-DP4-restricted CD4+ T cell responses were elicited after vaccination with NY-ESO-1(157-170) peptide (emulsified in IFA) in patients with NY-ESO-1-expressing epithelial ovarian cancer. These vaccine-induced CD4+ T cells were detectable from effector/memory populations without requirement for in vitro CD4+CD25+ T cell depletion. However, they were only able to recognize NY-ESO-1(157-170) peptide but not naturally processed NY-ESO-1 protein and had much lower avidity compared with NY-ESO-1-specific pre-existing naive CD4+CD25- T cell precursors or spontaneously induced CD4+ T cell effectors of cancer patients with NY-ESO-1 Ab. We propose that vaccination with NY-ESO-1(157-170) peptide recruits low-avidity T cells with low sensitivity to Tregs and fails to modulate the suppressive effect of Tregs on high-avidity NY-ESO-1-specific T cell precursors.
我们最近报道,大多数个体中存在NY-ESO-1特异性初始CD4+ T细胞前体,但被CD4+CD25+调节性T细胞(Tregs)抑制,而针对NY-ESO-1的记忆性CD4+ T细胞效应细胞仅在对NY-ESO-1有自发抗体反应的癌症患者中发现。在本研究中,我们分析了肽疫苗接种后CD4+ T细胞诱导的机制及其与Tregs易感性的关系。在用表达NY-ESO-1的上皮性卵巢癌患者中,用NY-ESO-1(157-170)肽(乳化于IFA中)接种疫苗后,引发了特异性HLA-DP4限制性CD4+ T细胞反应。这些疫苗诱导的CD4+ T细胞可从效应/记忆群体中检测到,无需体外去除CD4+CD25+ T细胞。然而,它们只能识别NY-ESO-1(157-170)肽,而不能识别天然加工的NY-ESO-1蛋白,与NY-ESO-1特异性预先存在的初始CD4+CD25-T细胞前体或NY-ESO-1抗体阳性癌症患者自发诱导的CD4+ T细胞效应细胞相比,其亲和力要低得多。我们提出,用NY-ESO-1(157-170)肽接种疫苗招募了对Tregs敏感性低的低亲和力T细胞,并且未能调节Tregs对高亲和力NY-ESO-1特异性T细胞前体的抑制作用。